Michael B. Atkins, Md, Regarding The Long-Term Follow Up Of Checkmate-004 In Metastatic Melanoma

Michael B. Atkins, MD, regarding the long-term follow up of Checkmate-004 in metastatic melanoma

Michael B. Atkins, MD: New Therapies and New Questions for Metastatic Melanoma

Vital Options International

Melanoma & Immunotherapy: Ask Dr. Michael Atkins

MedStar Georgetown University Hospital

Dr. Atkins on Long-Term Outcomes of the CheckMate 204 Trial in Melanoma

Dr. Atkins on Long-Term Survival Benefit of Nivolumab/Ipilimumab in Advanced Melanoma

Michael Atkins, MD, discusses Checkmate-214 investigating nivolumab + ipilimumab in RCC patients

Dr. Hodi on Long-Term Follow-Up of Nivolumab in Patients With Melanoma

Advances in Melanoma Treatment in 2025

New Long-term Data 'Clearly Favor' Combination Ipilimumab/Nivolumab in Melanoma

Specific Patient Populations Benefit from Nivolumab/Ipilimumab Combo Therapy

Specialty Pharmacy Times

Dr. Sharpless on Managing Toxicities With Nivolumab/Ipilimumab in Melanoma

Dr. Michael Atkins on Immunotherapy or Targeted Therapy as First Treatment for Advanced Melanoma

4-year results from CheckMate 238: adjuvant nivo vs ipi in resected stage III/IV melanoma

CheckMate067 outcomes: Nivolumab plus ipilimumab in advanced melanoma

Dr. Atkins on Adjuvant Ipilimumab in Melanoma

Dr. Long on Nivolumab/Ipilimumab in Patients with Melanoma Brain Metastases

Longterm Benefits from Nivolumab and Ipilimumab Combination Therapy

Specialty Pharmacy Times

Dr. Michael A. Davies on Identifying Patients With Melanoma at Risk for Developing Brain Metastases

Targeted Oncology

Metastatic Melanoma: The Immunotherapy Approach

Dr. Jeffrey Weber on Potential Breakthrough "Cures" in Melanoma

Targeted Oncology